Uptake of bone modifying agents in patients with HER2+ metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registry.

Vanessa WongRichard de BoerCatherine DunnAngelyn AntonLaeeq MalikSally GreenbergBelinda YeoLouise NottIan M CollinsJavier TorresFrances BarnettMichelle NottagePeter GibbsSheau Wen Lok

Published in: Internal medicine journal (2021)

Three-quarters of Australian HER2+ MBC patients with bone metastases receive a BMA, often at different schedules than guidelines recommend. Further studies, including of all MBC subtypes, are warranted to better understand clinicians' prescribing rationale and potential consequences of current prescribing practice on SRE incidence. This article is protected by copyright. All rights reserved.

Keyphrases

metastatic breast cancer
primary care
adverse drug
electronic health record
bone mineral density
palliative care
risk factors
big data
clinical practice
clinical trial
emergency department
soft tissue
machine learning
risk assessment
human health
case control
climate change
bone regeneration
postmenopausal women